

# Dennis M Black

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/152383/dennis-m-black-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164  
papers

27,985  
citations

75  
h-index

167  
g-index

170  
ext. papers

31,154  
ext. citations

9.5  
avg, IF

6.55  
L-index

#	Paper	IF	Citations
164	Low cumulative disease activity is associated with higher bone mineral density in a majority Latinx and Asian US rheumatoid arthritis cohort.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 53, 151972	5.3	2
163	Outcomes post fragility fracture among members of an integrated healthcare organization. <i>Osteoporosis International</i> , <b>2021</b> , 1	5.3	0
162	Bisphosphonates and the risk of atypical femur fractures.. <i>Bone</i> , <b>2021</b> , 116297	4.7	2
161	A Prospective Open-Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study. <i>JBMR Plus</i> , <b>2021</b> , 5, e10510	3.9	1
160	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> , 36, 236-243	6.3	4
159	Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> ,	6.3	2
158	The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> ,	6.3	1
157	A novel effervescent formulation of oral weekly alendronate (70µg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. <i>Aging Clinical and Experimental Research</i> , <b>2021</b> , 33, 2529-2537	4.8	1
156	Zoledronate. <i>Bone</i> , <b>2020</b> , 137, 115390	4.7	12
155	History of alendronate. <i>Bone</i> , <b>2020</b> , 137, 115411	4.7	12
154	Increases in PYY and uncoupling of bone turnover are associated with loss of bone mass after gastric bypass surgery. <i>Bone</i> , <b>2020</b> , 131, 115115	4.7	9
153	Bone mineral density as a surrogate biomarker for fracture risk reduction - Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 876	18.1	0
152	Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 672-682	18.1	40
151	Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes. <i>Journal of Bone and Mineral Research</i> , <b>2020</b> , 35, 2363-2371	6.3	7
150	Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 743-753	59.2	70
149	Non-contrast cardiac CT-based quantitative evaluation of epicardial and intra-thoracic fat in healthy, recently menopausal women: Reproducibility data from the Kronos Early Estrogen Prevention Study. <i>Journal of Cardiovascular Computed Tomography</i> , <b>2020</b> , 14, 55-59	2.8	2
148	Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 1977-1978	6.3	1

147	Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 632-642	6.3	96
146	Effect of Insulin Resistance on BMD and Fracture Risk in Older Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 3303-3310	5.6	31
145	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 1595-1622	5.6	259
144	Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. <i>Endocrine Reviews</i> , <b>2019</b> , 40, 333-368	27.2	92
143	The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?. <i>Menopause</i> , <b>2019</b> , 26, 1071-1084	5.5	55
142	Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 810-816	6.3	15
141	Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 1291-1301	6.3	46
140	Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial. <i>Journal of Pediatrics</i> , <b>2018</b> , 198, 201-208.e3	3.6	8
139	Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture Occur Early and Particularly Impact Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 975-986	6.3	60
138	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 634-642	6.3	30
137	The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 389-395	6.3	40
136	Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 63-69	6.3	42
135	Reply to: Indications of Increased Vertebral Fracture Risk in Patients With Type 2 Diabetes. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 183	6.3	2
134	The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age. <i>Journal of Pediatrics</i> , <b>2017</b> , 183, 19-25.e2	3.6	21
133	Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 200-210	6.4	96
132	Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1471-1479	11.5	40
131	Bone Marrow Fat Changes After Gastric Bypass Surgery Are Associated With Loss of Bone Mass. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 2239-2247	6.3	39
130	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 3-10	6.3	94

129	Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 17-23	6.3	57
128	Hospitalizations in Pediatric and Adult Patients for All Cancer Type in Italy: The EPIKIT Study under the E.U. COHEIRS Project on Environment and Health. <i>International Journal of Environmental Research and Public Health</i> , <b>2017</b> , 14,	4.6	1
127	Prevalence of osteoporosis in the Italian population and main risk factors: results of BoneTour Campaign. <i>BMC Musculoskeletal Disorders</i> , <b>2016</b> , 17, 396	2.8	16
126	Overlapping Surgery in the Ambulatory Orthopaedic Setting. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2016</b> , 98, 1859-1867	5.6	57
125	What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1500-3	6.3	31
124	Association of 3D Geometric Measures Derived From Quantitative Computed Tomography With Hip Fracture Risk in Older Men. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1550-8	6.3	14
123	Clinical Practice. Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 254-62	59.2	675
122	Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. <i>Journal of Pediatrics</i> , <b>2016</b> , 168, 23-29.e4	3.6	57
121	Osteoporosis and Bone Biology <b>2016</b> , 1323-1364		5
120	Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1767-73	6.3	19
119	Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. <i>Drugs and Aging</i> , <b>2016</b> , 33, 347-53	4.7	19
118	Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. <i>Physiological Genomics</i> , <b>2016</b> , 48, 33-41	3.6	20
117	Degree of Trauma Differs for Major Osteoporotic Fracture Events in Older Men Versus Older Women. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 204-7	6.3	21
116	Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns. <i>Journal of Pediatrics</i> , <b>2016</b> , 177, 97-102.e2	3.6	43
115	Abdominal aortic calcification and risk of fracture among older women - The SOF study. <i>Bone</i> , <b>2015</b> , 81, 16-23	4.7	20
114	Inhaled nitric oxide increases urinary nitric oxide metabolites and cyclic guanosine monophosphate in premature infants: relationship to pulmonary outcome. <i>American Journal of Perinatology</i> , <b>2015</b> , 32, 225-32	3.3	10
113	Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 570-4	6.3	15
112	Predicting Hip Fracture Type With Cortical Bone Mapping (CBM) in the Osteoporotic Fractures in Men (MrOS) Study. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 2067-77	6.3	44

111	Association between femur size and a focal defect of the superior femoral neck. <i>Bone</i> , <b>2015</b> , 81, 60-66	4.7	8
110	Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization of Vitamin D Status. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 1377-85	6.3	103
109	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001833; discussion e1001833	11.6	260
108	The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 934-44	6.3	152
107	A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 4094-100	5.6	8
106	Fracture risk in diabetic elderly men: the MrOS study. <i>Diabetologia</i> , <b>2014</b> , 57, 2057-65	10.3	174
105	Prediction models of prevalent radiographic vertebral fractures among older women. <i>Journal of Clinical Densitometry</i> , <b>2014</b> , 17, 378-85	3.5	13
104	Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2014</b> , 161, 249-60	8	215
103	The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 40, 331-41	4.3	20
102	Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 4546-54 <sup>6</sup>	5.6	89
101	High hip fracture risk in men with severe aortic calcification: MrOS study. <i>Journal of Bone and Mineral Research</i> , <b>2014</b> , 29, 968-75	6.3	25
100	Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1126-34	11.5	94
99	Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1550-7	11.5	42
98	Prediction models of prevalent radiographic vertebral fractures among older men. <i>Journal of Clinical Densitometry</i> , <b>2014</b> , 17, 449-57	3.5	16
97	Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 1348-54	6.3	87
96	Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , <b>2013</b> , 24, 1503-11	5.3	8
95	Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. <i>Osteoporosis International</i> , <b>2013</b> , 24, 329-38	5.3	16
94	Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 659-67	5.6	43

93	The search for the optimal anabolic osteoporosis therapy. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 2263-5	6.3	8
92	BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 1319-27	6.3	39
91	A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation. <i>Clinical Cases in Mineral and Bone Metabolism</i> , <b>2013</b> , 10, 187-90		2
90	Height loss in older women: risk of hip fracture and mortality independent of vertebral fractures. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 153-9	6.3	26
89	Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. <i>Osteoporosis International</i> , <b>2012</b> , 23, 53-8	5.3	25
88	Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 2051-3	59.2	202
87	Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 3522-9	5.6	39
86	The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 243-54	6.3	397
85	Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 808-16	6.3	139
84	Incidence and demography of femur fractures with and without atypical features. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 977-86	6.3	120
83	Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 1487-93	6.3	11
82	Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 1627-34	6.3	92
81	Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 2414-22	5.6	19
80	Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2011</b> , 14, 68-73	3.5	5
79	Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. <i>Bone</i> , <b>2011</b> , 48, 1298-304	4.7	13
78	Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 12-8	6.3	78
77	The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 683-8	6.3	35
76	Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 984-92	6.3	20

75	Effects of antiresorptive treatment on nonvertebral fracture outcomes. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 2411-8	6.3	36
74	Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 1627-32	5.6	93
73	Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 2184-92	27.4	443
72	Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, E1982-9	5.6	86
71	Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1761-71	59.2	383
70	The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. <i>Journal of the American Dental Association</i> , <b>2010</b> , 141, 1365-70	1.9	76
69	Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 976-82	6.3	189
68	Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. <i>Journal of the American Geriatrics Society</i> , <b>2010</b> , 58, 292-9	5.6	91
67	Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 921-8	2.5	44
66	Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 3215-25	5.6	75
65	Pentosidine and increased fracture risk in older adults with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2380-6	5.6	225
64	Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 389-97	6.3	116
63	Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 1544-51	6.3	94
62	Defining a Reference Population—No Easy Task. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 1639-1639	6.3	1
61	Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 2166-72	5.6	47
60	Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 1326-33	6.3	163
59	Prevalent vertebral fractures in black women and white women. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 1458-67	6.3	77
58	Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 1442-8	6.3	25

57	Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 1974-82	6.3	165
56	Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1809-22	59.2	2094
55	Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?. <i>Nature Clinical Practice Rheumatology</i> , <b>2007</b> , 3, 378-9		4
54	Alendronate and atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1895-6	59.2	184
53	Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 942-7	5.6	22
52	Use of Alendronate After 5 Years of TreatmentReply. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 1979	27.4	1
51	Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 2927-38	27.4	965
50	The effects of organic nitrates on osteoporosis: a randomized controlled trial [ISRCTN94484747]. <i>Trials</i> , <b>2006</b> , 7, 10	2.8	8
49	Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. <i>Journal of Bone and Mineral Research</i> , <b>2006</b> , 21, 292-9	6.3	131
48	Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. <i>Mayo Clinic Proceedings</i> , <b>2005</b> , 80, 343-9	6.4	81
47	One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 555-65	59.2	477
46	Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 131-40	6.3	83
45	Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 971-6	6.3	72
44	Hip fracture in women without osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 2787-93	5.6	451
43	Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women 65 Years of Age: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 131-140	6.3	149
42	Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 1259-69	6.3	201
41	Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 1250-8	6.3	293
40	Vignettes in osteoporosis: a road map to successful therapeutics. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 3-10	6.3	4



39	Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 3482-6	5.6	79
38	The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1207-15	59.2	991
37	Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. <i>Bone</i> , <b>2003</b> , 33, 293-300	4.7	144
36	Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. <i>Journal of the American Geriatrics Society</i> , <b>2002</b> , 50, 409-15	5.6	49
35	Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. <i>Journal of Bone and Mineral Research</i> , <b>2002</b> , 17, 1-10	6.3	336
34	Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. <i>Endocrine Reviews</i> , <b>2002</b> , 23, 508-16	27.2	351
33	Clinical use of bone densitometry: scientific review. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 1889-97	27.4	548
32	Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 281-9	2.4	590
31	An assessment tool for predicting fracture risk in postmenopausal women. <i>Osteoporosis International</i> , <b>2001</b> , 12, 519-28	5.3	354
30	A normative reference database study for Pronosco X-posure System. <i>Journal of Clinical Densitometry</i> , <b>2001</b> , 4, 5-12	3.5	51
29	Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. <i>Journal of the American Geriatrics Society</i> , <b>2000</b> , 48, 241-9	5.6	320
28	Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial. <i>Journal of the American Geriatrics Society</i> , <b>2000</b> , 48, 1126-31	5.6	16
27	Epidemiology of Fractures and Assessment of Fracture Risk. <i>Clinics in Laboratory Medicine</i> , <b>2000</b> , 20, 439-454	4.5	41
26	Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 4118-24	5.6	730
25	Vertebral fracture prevalence among women screened for the Fracture Intervention Trial and a simple clinical tool to screen for undiagnosed vertebral fractures. Fracture Intervention Trial Research Group. <i>Mayo Clinic Proceedings</i> , <b>2000</b> , 75, 888-96	6.4	79
24	Epidemiology of fractures and assessment of fracture risk. <i>Clinics in Laboratory Medicine</i> , <b>2000</b> , 20, 439-531	5.1	12
23	Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. <i>Journal of Bone and Mineral Research</i> , <b>1999</b> , 14, 90-101	6.3	143
22	Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. <i>Journal of Bone and Mineral Research</i> , <b>1999</b> , 14, 821-8	6.3	583

21	Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , <b>1999</b> , 14, 1404-10	6.3	128
20	Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. <i>Osteoporosis International</i> , <b>1999</b> , 10, 259-64	5.3	517
19	Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 1246-54		240
18	Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group. <i>Journal of Bone and Mineral Research</i> , <b>1998</b> , 13, 1167-74	6.3	119
17	Correlates of kyphosis in older women. The Fracture Intervention Trial Research Group. <i>Journal of the American Geriatrics Society</i> , <b>1997</b> , 45, 682-7	5.6	106
16	Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. <i>Journal of Bone and Mineral Research</i> , <b>1996</b> , 11, 984-96	6.3	466
15	Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. <i>Lancet, The</i> , <b>1996</b> , 348, 1535-41	4.0	3001
14	Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , <b>1995</b> , 10, 890-902	6.3	186
13	Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , <b>1995</b> , 10, 1778-87	6.3	242
12	Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 767-73	59.2	2920
11	Insulin-like growth factor 1 and functional status in healthy older men. <i>Journal of the American Geriatrics Society</i> , <b>1995</b> , 43, 1350-5	5.6	67
10	Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , <b>1993</b> , 8, 1211-7	6.3	502
9	Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. <i>Journal of Bone and Mineral Research</i> , <b>1992</b> , 7, 449-56	6.3	358
8	Age-related decrements in bone mineral density in women over 65. <i>Journal of Bone and Mineral Research</i> , <b>1992</b> , 7, 625-32	6.3	236
7	Axial and appendicular bone density predict fractures in older women. <i>Journal of Bone and Mineral Research</i> , <b>1992</b> , 7, 633-8	6.3	366
6	Appendicular bone mineral and a woman's lifetime risk of hip fracture. <i>Journal of Bone and Mineral Research</i> , <b>1992</b> , 7, 639-46	6.3	110
5	A new approach to defining normal vertebral dimensions. <i>Journal of Bone and Mineral Research</i> , <b>1991</b> , 6, 883-92	6.3	184
4	Prevalence of ABO maternal-infant incompatibility in Asians, Blacks, Hispanics and Caucasians. <i>Vox Sanguinis</i> , <b>1988</b> , 54, 181-3	3.1	22

- |   |   |     |     |
|---|---|-----|-----|
| 3 | Recovery of function after hip fracture. The role of social supports. <i>Journal of the American Geriatrics Society</i> , <b>1988</b> , 36, 801-6 | 5.6 | 118 |
| 2 | A Distributed Data Processing System for a Multicenter Clinical Trial. <i>Drug Information Journal</i> , <b>1986</b> , 20, 83-92                  |     | 5   |
| 1 | Resources in Geriatric Drug Research. <i>Drug Information Journal</i> , <b>1985</b> , 19, 421-427   |     | 5   |